Delayed
Nasdaq
16:50:04 26/06/2024 BST
|
5-day change
|
1st Jan Change
|
2.57
USD
|
+7.98%
|
|
-2.28%
|
+42.78%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7.521
|
233.5
|
63.09
|
31.37
|
43.56
|
91.65
|
-
|
-
|
Enterprise Value (EV)
1 |
7.521
|
233.5
|
63.09
|
31.37
|
43.56
|
91.65
|
91.65
|
91.65
|
P/E ratio
|
-0.43
x
|
-0.98
x
|
-1.89
x
|
-0.37
x
|
-1.1
x
|
-1.84
x
|
-3.82
x
|
-3.26
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
2.75
x
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
2.75
x
|
-
|
EV / EBITDA
|
-584,522
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-542,761
x
|
-15,347,759
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
0.79
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
720
|
15,160
|
14,307
|
13,757
|
24,198
|
38,507
|
-
|
-
|
Reference price
2 |
10.44
|
15.40
|
4.410
|
2.280
|
1.800
|
2.380
|
2.380
|
2.380
|
Announcement Date
|
17/03/20
|
30/03/21
|
24/03/22
|
30/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
33.33
|
-
|
EBITDA
|
-12.87
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.18
|
-18.46
|
-36.87
|
-88.43
|
-43
|
-49.04
|
-13.93
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-41.8%
|
-
|
Earnings before Tax (EBT)
1 |
-16.01
|
-23.22
|
-36.86
|
-87.97
|
-40.33
|
-48
|
-13.33
|
-
|
Net income
1 |
-16.01
|
-22.81
|
-34.51
|
-87.97
|
-40.33
|
-47.84
|
-33.56
|
-70.7
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-100.67%
|
-
|
EPS
2 |
-24.48
|
-15.72
|
-2.330
|
-6.160
|
-1.640
|
-1.295
|
-0.6233
|
-0.7300
|
Free Cash Flow
|
-13.86
|
-15.21
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
17/03/20
|
30/03/21
|
24/03/22
|
30/03/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.385
|
-9.859
|
-9.283
|
-10.6
|
-58.69
|
-11.11
|
-10.35
|
-11.2
|
-10.34
|
-10.87
|
-12.45
|
-12.77
|
-12.94
|
-16.5
|
-19.55
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-9.385
|
-9.864
|
-9.247
|
-10.47
|
-58.38
|
-10.77
|
-9.579
|
-10.35
|
-9.626
|
-10.3
|
-12.3
|
-12.62
|
-12.79
|
-16.2
|
-19.25
|
Net income
1 |
-8.806
|
-9.864
|
-9.247
|
-10.47
|
-58.38
|
-10.77
|
-9.579
|
-10.35
|
-9.626
|
-10.3
|
-12
|
-12.61
|
-12.93
|
-16.2
|
-19.25
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6000
|
-0.6900
|
-0.6500
|
-0.7300
|
-4.090
|
-0.7500
|
-0.4000
|
-0.3500
|
-0.2900
|
-0.3400
|
-0.3225
|
-0.3200
|
-0.3250
|
-0.3700
|
-0.4400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/03/22
|
12/05/22
|
11/08/22
|
14/11/22
|
30/03/23
|
11/05/23
|
10/08/23
|
09/11/23
|
28/03/24
|
13/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-13.9
|
-15.2
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
13.10
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
17/03/20
|
30/03/21
|
24/03/22
|
30/03/23
|
28/03/24
|
-
|
-
|
-
|
Last Close Price
2.38
USD Average target price
14
USD Spread / Average Target +488.24% Consensus |
1st Jan change
|
Capi.
|
---|
| +42.78% | 91.65M | | +17.16% | 122B | | +21.83% | 116B | | +22.18% | 27.03B | | -21.47% | 20.36B | | -16.89% | 16.43B | | -18.33% | 15.91B | | -44.74% | 15.6B | | +63.01% | 14.94B | | +3.04% | 13.59B |
Bio Therapeutic Drugs
|